Health Science Startups Toronto: Difference between revisions
From Federal Burro of Information
Jump to navigationJump to search
(Created page with " {| class="wikitable" ! Startup !! Description !! Founded !! Funding |- | BenchSci || Uses AI to empower scientists to run more successful experiments to accelerate drug discovery || 2012 || Over $45 million |- | ACTO || An omnichannel education platform for life sciences companies || 2014 || Over $11 million |- | Nanology Labs || A pharmaceutical company that harnesses advanced nanotechnology to detect and treat cancers at the early stages || 2016 || Over $3 million |-...") |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
{| class="wikitable" | {| class="wikitable sortable" | ||
! Startup !! Description !! Founded !! Funding | ! Startup !! Description !! Founded !! Funding | ||
|- | |- | ||
| Line 23: | Line 23: | ||
|- | |- | ||
| Phycus Biotechnologies || Provides a bio-conversion platform intended to convert CO2 and diverting GHG emissions from large scale emitters || 2016 || Over $2 million | | Phycus Biotechnologies || Provides a bio-conversion platform intended to convert CO2 and diverting GHG emissions from large scale emitters || 2016 || Over $2 million | ||
|} | |||
{| class="wikitable sortable" | |||
! Startup !! Description !! Founded !! Funding | |||
|- | |||
| Synaptive Medical || A medical device and technology company that develops products and services for neurosurgery, neurology, and trauma care || 2012 || Over $200 million | |||
|- | |||
| BlueRock Therapeutics || A biotechnology company that develops cell therapies for degenerative diseases. Acquired by Bayer in 2019 for $1 billion || 2016 || N/A | |||
|- | |||
| Deep Genomics || A biotechnology company that uses AI to discover and develop novel therapies for genetic diseases || 2015 || Over $180 million | |||
|- | |||
| Figure 1 || A social network for healthcare professionals to share and discuss clinical cases || 2012 || Over $20 million | |||
|- | |||
| League || A digital health platform that connects employers and employees with health benefits, wellness programs, and healthcare providers || 2014 || Over $70 million | |||
|- | |||
| NuraLogix || A software company that uses AI and facial recognition to measure human emotions and health conditions || 2015 || Over $10 million | |||
|- | |||
| Swift Medical || A software company that provides wound care management solutions for healthcare providers || 2015 || Over $35 million | |||
|- | |||
| WinterLight Labs || A software company that uses AI and speech analysis to detect and monitor cognitive and mental health conditions || 2015 || Over $10 million | |||
|- | |||
| Xanadu || A quantum computing company that develops photonic quantum processors and software tools || 2016 || Over $100 million | |||
|- | |||
| Zymeworks || A biotechnology company that develops antibody-based therapies for cancer and autoimmune diseases. Went public in 2017, raising over $200 million in its IPO || 2003 || N/A | |||
|} | |} | ||
Latest revision as of 03:29, 9 August 2023
| Startup | Description | Founded | Funding |
|---|---|---|---|
| BenchSci | Uses AI to empower scientists to run more successful experiments to accelerate drug discovery | 2012 | Over $45 million |
| ACTO | An omnichannel education platform for life sciences companies | 2014 | Over $11 million |
| Nanology Labs | A pharmaceutical company that harnesses advanced nanotechnology to detect and treat cancers at the early stages | 2016 | Over $3 million |
| Geneseeq | Uses NGS technologies to help physicians make meaningful decisions for cancer treatment | 2012 | Over $100 million |
| Meta | An intelligent system that can read, understand, and reason over scientific and technical literature. Acquired by the Chan Zuckerberg Initiative in 2017 | N/A | N/A |
| NEXT Integrative Minds Life Sciences Ltd. | A personal performance improvement system that works by training users to self-direct their neuroplasticity | 2017 | Over $2 million |
| Vasomune Inc | A biotechnology company, developing therapies for blood vessel diseases – vascular dysfunction and destabilization | 2010 | Over $10 million |
| GeneYouIn | A Canadian personalized medicine company, has developed a genome analytics and reporting platform called Pillcheck | 2013 | Over $2 million |
| Shift Health | A healthcare strategy consultancy for Healthcare & Life Sciences Leaders | 2014 | Over $5 million |
| Phycus Biotechnologies | Provides a bio-conversion platform intended to convert CO2 and diverting GHG emissions from large scale emitters | 2016 | Over $2 million |
| Startup | Description | Founded | Funding |
|---|---|---|---|
| Synaptive Medical | A medical device and technology company that develops products and services for neurosurgery, neurology, and trauma care | 2012 | Over $200 million |
| BlueRock Therapeutics | A biotechnology company that develops cell therapies for degenerative diseases. Acquired by Bayer in 2019 for $1 billion | 2016 | N/A |
| Deep Genomics | A biotechnology company that uses AI to discover and develop novel therapies for genetic diseases | 2015 | Over $180 million |
| Figure 1 | A social network for healthcare professionals to share and discuss clinical cases | 2012 | Over $20 million |
| League | A digital health platform that connects employers and employees with health benefits, wellness programs, and healthcare providers | 2014 | Over $70 million |
| NuraLogix | A software company that uses AI and facial recognition to measure human emotions and health conditions | 2015 | Over $10 million |
| Swift Medical | A software company that provides wound care management solutions for healthcare providers | 2015 | Over $35 million |
| WinterLight Labs | A software company that uses AI and speech analysis to detect and monitor cognitive and mental health conditions | 2015 | Over $10 million |
| Xanadu | A quantum computing company that develops photonic quantum processors and software tools | 2016 | Over $100 million |
| Zymeworks | A biotechnology company that develops antibody-based therapies for cancer and autoimmune diseases. Went public in 2017, raising over $200 million in its IPO | 2003 | N/A |
